全文获取类型
收费全文 | 3790769篇 |
免费 | 323346篇 |
国内免费 | 39231篇 |
专业分类
耳鼻咽喉 | 50908篇 |
儿科学 | 110950篇 |
妇产科学 | 94644篇 |
基础医学 | 580947篇 |
口腔科学 | 101618篇 |
临床医学 | 354853篇 |
内科学 | 656032篇 |
皮肤病学 | 96294篇 |
神经病学 | 312322篇 |
特种医学 | 150200篇 |
外国民族医学 | 676篇 |
外科学 | 569649篇 |
综合类 | 172087篇 |
现状与发展 | 108篇 |
一般理论 | 2291篇 |
预防医学 | 303824篇 |
眼科学 | 89018篇 |
药学 | 279690篇 |
445篇 | |
中国医学 | 33949篇 |
肿瘤学 | 192841篇 |
出版年
2021年 | 71430篇 |
2020年 | 48290篇 |
2019年 | 68320篇 |
2018年 | 81265篇 |
2017年 | 64203篇 |
2016年 | 68836篇 |
2015年 | 88538篇 |
2014年 | 126530篇 |
2013年 | 189719篇 |
2012年 | 116903篇 |
2011年 | 118934篇 |
2010年 | 134866篇 |
2009年 | 136256篇 |
2008年 | 96723篇 |
2007年 | 99397篇 |
2006年 | 109237篇 |
2005年 | 103966篇 |
2004年 | 99530篇 |
2003年 | 90205篇 |
2002年 | 78804篇 |
2001年 | 115601篇 |
2000年 | 108828篇 |
1999年 | 107581篇 |
1998年 | 69001篇 |
1997年 | 66719篇 |
1996年 | 63611篇 |
1995年 | 58924篇 |
1994年 | 52738篇 |
1993年 | 48644篇 |
1992年 | 73621篇 |
1991年 | 69730篇 |
1990年 | 66481篇 |
1989年 | 65582篇 |
1988年 | 61257篇 |
1987年 | 59730篇 |
1986年 | 57039篇 |
1985年 | 56483篇 |
1984年 | 50756篇 |
1983年 | 45966篇 |
1982年 | 42405篇 |
1981年 | 39893篇 |
1980年 | 37693篇 |
1979年 | 43034篇 |
1978年 | 37388篇 |
1977年 | 34290篇 |
1976年 | 31050篇 |
1975年 | 30706篇 |
1974年 | 32430篇 |
1973年 | 31097篇 |
1972年 | 29517篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
62.
目的 基于网络药理学和分子对接技术探究黄芪-赤芍配伍对治疗慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)的作用机制。方法 利用TCMSP,Pharmmaper数据库,筛选黄芪-赤芍治疗COPD的活性成分和潜在靶点;结合Genecards数据库挖掘的COPD相关靶点,对黄芪-赤芍药对与COPD靶点进行PPI网络构建,交互处理得到黄芪-赤芍药对治疗COPD的关键靶点,并进行GO分析和KEGG通路富集分析;并采用分子对接技术将主要活性成分与TNF-α(肿瘤坏死因子),IL-6(白细胞介素6)等进行分子对接;最后利用A549炎症细胞与人脐静脉内皮细胞缺氧损伤模型进行体外细胞实验对结果加以验证。结果 黄芪-赤芍药对中44个有效成分作用于COPD,核心成分为:槲皮素、山奈酚、丁子香萜、芍药苷、(2R,3R)-4-methoxyl-distylin、二氢异黄酮;黄芪-赤芍药对通过IL6、PTGS2、TNF等113个靶蛋白,调控Ras、PI3KAkt、IL-17等多条信号通路治疗COPD,且分子对接结果显示槲皮素、山奈酚、丁子香萜、芍药苷与IL-6、PTGS2、TNF大分子蛋白有良好的结合性,体外细胞试验证实,槲皮素与山奈酚均能减少IL-8,MMP-9炎症因子的分泌,具有不同程度的抗炎效果;芍药苷有明显的扩血管、抗血栓之效。结论 黄芪-赤芍药对治疗COPD具有多成分、多靶点、多通路、整体调节的作用特点。初步揭示了黄芪-赤芍药对通过抑制炎症反应、调节上皮细胞生长增强保护屏障等预测出黄芪-赤芍药对治疗COPD的潜在作用机制,以期为其活性成分的药效物质基础提供理论研究和思路。 相似文献
63.
Depeng Meng Yichen Meng Bingyang Li Guigang Zeng Bin Zhang Chunlin Hou Haodong Lin Yueping Ouyang 《Journal of orthopaedic science》2021,26(3):409-414
BackgroundComminuted patellar fractures are not rare, and the ideal treatment method remains controversial. The present study was conducted to evaluate effects and compare complications of two different methods used to treat comminuted patellar fractures.MethodsFrom March 2010 to August 2016, 102 cases of 34-C2 or 34-C3 comminuted patellar fractures were treated at our hospital, wherein patients received two different treatments: titanium cable tension band with cerclage method (group A) and intrafragmentary screws with X-shaped plating technique (group B). At follow-ups, articular step-off, range of motion (ROM), Lysholm scores, time of union, and complications were recorded and analyzed. Radiographic and clinical data as well as rate of complications were statistically analyzed.ResultsIn total, 87 patients were included in the final analysis (n = 47 in group A and n = 40 in group B). No significant differences were noted in terms of cost of implant, age, gender, rate of 34-C3 fractures, rate of layered inferior pole fractures, postoperative articular step-off and union time. At 2-year follow-up, average Lysholm scores, ROM and rate of complications were (89.0 ± 4.5), (122°±12°) and (27.7%) in group A and (90.2 ± 3.9), (124°±11°) and (17.5%) in group B, respectively, with no significant differences (p > 0.05). The mean time of surgery in group B was shorter than that in group A with significant difference (p < 0.05).ConclusionsTreatment using the intrafragmentary screws and plate method for amenable comminuted patellar fractures achieved similar complication rate and favorable functional outcomes at the 2-year follow-up, which was comparable to the titanium cable tension band with cerclage method. Thus, the intrafragmentary screws and plate method is effective, safe and convenient for 34-C2/C3 comminuted patellar fractures, especially appropriate for patients with layered fragments. 相似文献
64.
IntroductionHip displacement is common in cerebral palsy (CP) and is related to the severity of neurological and functional impairment. It is a silent, but progressive disease, and can result in significant morbidity and decreased quality of life, if left untreated. The pathophysiology of hip displacement in CP is a combination of hip flexor-adductor muscle spasticity, abductor muscle weakness, and delayed weight-bearing, resulting in proximal femoral deformities and progressive acetabular dysplasia. Due to a lack of symptoms in the early stages of hip displacement, the diagnosis is easily missed. Awareness of this condition and regular surveillance by clinical examination and serial radiographs of the hips are the key to early diagnosis and treatment.Hip surveillance programmesSeveral population-based studies from around the world have demonstrated that universal hip surveillance in children with CP allows early detection of hip displacement and appropriate early intervention, with a resultant decrease in painful dislocations. Global hip surveillance models are based upon the patients’ age, functional level determined by the Gross Motor Function Classification system (GMFCS), gait classification, standardized clinical exam, and radiographic indices such as the migration percentage (MP), as critical indicators of progressive hip displacement.ConclusionDespite 25 years of evidence showing the efficacy of established hip surveillance programmes, there is poor awareness among healthcare professionals in India about the importance of regular hip surveillance in children with CP. There is a need for professional organizations to develop evidence-based guidelines for hip surveillance which are relevant to the Indian context. 相似文献
65.
Yuxiang Ma Wenfeng Fang Hongyun Zhao Sai Praneeth Bathena Amol Tendolkar Jennifer Sheng Li Zhang 《The oncologist》2021,26(4):e549-e566
Lessons Learned
- The overall safety profiles of ipilimumab 3 mg/kg and 10 mg/kg administered every 3 weeks, were consistent between Chinese patients with solid tumors in the current study and patients from previous U.S. ipilimumab monotherapy studies. No new safety signals were identified.
- The mean systemic exposures to ipilimumab (assessed by first dose area under the curve during the dosing interval and maximum serum concentration) were numerically lower in the Chinese patient population than in U.S. patients for both 3 mg/kg and 10 mg/kg doses; however, the range of serum concentrations in the Chinese and U.S. populations overlapped (3 mg/kg and 10 mg/kg), suggesting that ipilimumab pharmacokinetics was ethnically insensitive in this study.
66.
67.
68.
69.
Karen Kayser Ariel Washington Lesley M. Harris Barbara Head 《Journal of psychosocial oncology》2021,39(1):17-34
Abstract